Medicine Information

Cabanib

Name: Cabanib
Brand: Cabanib
Rating: 4.5 (117 reviews)

Capsule60 mgTyrosine Kinase Inhibitor, Antineoplastic agentATC: L01XE23

Generic Name

Cabozantinib 60 mg capsule

Manufacturer

Beacon Pharmaceuticals Limited

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
cabanib 60 mg capsule	৳ 350.00	N/A

Description

Overview of the medicine

Cabanib (Cabozantinib) is a kinase inhibitor indicated for various types of cancer. It targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth, metastasis, and angiogenesis.

Uses & Indications

Medullary Thyroid Carcinoma (MTC)

Renal Cell Carcinoma (RCC) in previously treated patients

Hepatocellular Carcinoma (HCC) in patients previously treated with sorafenib

Differentiated Thyroid Cancer (DTC) that has progressed following prior VEGFR-targeted therapy and is refractory to radioactive iodine.

Dosage

Adults

MTC/HCC/DTC: 60 mg orally once daily. RCC: 60 mg orally once daily (dose adjustments for adverse reactions may be required).

Elderly

No specific dosage adjustment required based on age alone.

Renal_impairment

No dosage adjustment for mild to moderate impairment. Not studied in severe renal impairment.

How to Take

Take orally with or without food. Do not eat for at least 2 hours before and 1 hour after taking Cabanib. Swallow capsules whole. Do not open, crush, or chew capsules.

Mechanism of Action

Cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR1, VEGFR2, VEGFR3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, and FLT3. These kinases are involved in oncogenesis, metastasis, tumor angiogenesis, and the maintenance of the tumor microenvironment.

Pharmacokinetics

Onset

Not precisely defined for kinase inhibitors; clinical effects observed over weeks.

Excretion

Primarily via feces (81%), with a minor amount via urine (10%).

Half life

Approximately 99 hours.

Absorption

Oral administration. Tmax is 2-4 hours. High-fat meal increases AUC by 42% and Cmax by 29%.

Metabolism

Primarily hepatic, mainly by CYP3A4.

Side Effects

Contraindications

Known hypersensitivity to cabozantinib or any component of the formulation.

Drug Interactions

Strong CYP3A4 inducers (e.g., rifampicin, phenytoin)

May decrease cabozantinib exposure. Avoid co-administration or increase cabozantinib dose.

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)

May increase cabozantinib exposure. Avoid co-administration or reduce cabozantinib dose.

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.

Overdose

No specific antidote. Management involves symptomatic and supportive care.

Pregnancy & Lactation

Pregnancy: May cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose. Lactation: Advise women not to breastfeed during treatment and for 4 months after the last dose.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

60 mg capsules (e.g., 30 capsules per bottle)

Shelf Life

Typically 24-36 months.

Availability

Hospitals, specialized pharmacies

Approval Status

FDA Approved

Patent Status

Patented

Clinical Trials

Extensive clinical trials (e.g., ZETA, METEOR, CELESTIAL, COSMIC-312) supported the approval of cabozantinib for its various indications.

Lab Monitoring

Blood pressure monitoring
Complete blood count (CBC) with differential
Thyroid stimulating hormone (TSH) levels
Liver function tests (LFTs)
Renal function tests
Urinalysis for proteinuria

Doctor Notes

Careful monitoring for adverse events, especially GI events, hypertension, and hemorrhage.
Dose adjustments or interruption may be required based on tolerability.
Educate patients on potential side effects and when to seek medical attention.

Patient Guidelines

Adhere strictly to the prescribed dosage and schedule.
Report any unusual bleeding, severe abdominal pain, or other new/worsening symptoms promptly to your doctor.
Do not stop treatment without consulting your doctor.
Maintain good oral hygiene to reduce risk of osteonecrosis of the jaw.

Missed Dose Advice

If a dose is missed, do not take the missed dose if the next scheduled dose is less than 12 hours away. Resume the regular dosing schedule. Do not take two doses to make up for a missed dose.